Latest Ratios: P/E Ratio -3.0x · EV/EBITDA N/A · ROE -225.6%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $36M | $30M | $30M | $47M | $43M | $86M | — | — |
| Enterprise Value | $29M | $23M | $24M | $46M | $38M | $71M | — | — |
| P/E Ratio → | -2.96 | — | — | — | — | — | — | — |
| P/S Ratio | 32.09 | 26.43 | 708.18 | — | — | — | — | — |
| P/B Ratio | 6.18 | 5.47 | 6.80 | — | 6.90 | 5.63 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 20.27 | 548.27 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.9% | 70.9% | 100.0% | — | — | — | — | — |
| Operating Margin | -1114.0% | -1114.0% | -25511.6% | — | — | — | — | — |
| Net Profit Margin | -994.5% | -994.5% | -20497.7% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -225.6% | -225.6% | -1192.7% | -647.0% | -91.9% | -1825.1% | — | -262.0% |
| ROA | -137.8% | -137.8% | -183.9% | -234.4% | -84.0% | -69.5% | -181.5% | -169.1% |
| ROIC | — | — | — | — | -773.7% | — | — | — |
| ROCE | -202.7% | -202.7% | -337.5% | -353.1% | -92.5% | -86.1% | — | -265.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.06 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.28 | -1.54 | — | -0.71 | -0.99 | — | -1.44 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -105.52 | -174.56 | -6.58 | -5.43 | — |
Net cash position: cash ($7M) exceeds total debt ($107000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.02 | 4.02 | 4.10 | 1.25 | 6.59 | 17.36 | 0.47 | 2.81 |
| Quick Ratio | 3.93 | 3.93 | 4.10 | 1.25 | 6.59 | 17.36 | 0.47 | 2.81 |
| Cash Ratio | 3.58 | 3.58 | 3.75 | 1.00 | 5.84 | 16.20 | 0.44 | 2.61 |
| Asset Turnover | — | 0.14 | 0.01 | — | — | — | — | — |
| Inventory Turnover | 1.73 | 1.73 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 45.18 | 365.00 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $35M | $24M | $21M | $18M | $18M | $17M | $17M |
Binary clinical trial outcome
Based on reported figures, the company trades at a price-to-sales ratio of 31.96, which, according to recent SEC filings, appears to be a valuation artifact of its pre-commercial status rather than a reflection of fundamental earnings power or sustainable growth expectations within the biotechnology sector.
The absence of meaningful earnings or recurring revenue renders traditional P/E and EV/EBITDA multiples non-informative for assessing intrinsic value. Investors should interpret the current P/S multiple as a premium paid for the potential of the TIGeR-PaC trial rather than a valuation of existing operational cash flows.
As reported in financial statements, the company's cash conversion cycle remains highly volatile, with recent data showing a negative CCC of -690 days, which suggests that standard efficiency metrics are currently distorted by the timing of clinical trial milestone payments rather than core operational performance.
The extreme fluctuations in days sales outstanding and days payable outstanding indicate that working capital is managed to support trial liquidity rather than to optimize supply chain efficiency. Analysts should monitor these figures primarily as indicators of cash management pressure rather than as proxies for operational productivity.
According to recent quarterly data, the current ratio has compressed from 9.07 in 2025Q1 to 7.15 in 2026Q1, signaling that the company's liquidity position is tightening as it continues to fund its high-intensity clinical development program without a corresponding inflow of commercial revenue.
While the current ratio appears superficially high, it is heavily dependent on a shrinking cash balance that is being consumed by R&D overhead. This trend warrants further investigation into the company's ability to maintain sufficient liquidity to reach its next clinical data readout without resorting to dilutive financing.
As indicated by the company's financial disclosures, the most commonly misapplied ratio for this business model is the price-to-sales multiple, which obscures the fact that current revenue is non-recurring and derived from clinical collaborations rather than a scalable, market-validated commercial product or service.
Using P/S to value a clinical-stage entity like RNXT risks misinterpreting transactional milestone payments as sustainable top-line growth. A probability-weighted net present value approach, focusing on the potential market size of the TAMP technology in pancreatic cancer, would be a more appropriate analytical framework than revenue-based multiples.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RNXT stock.
RenovoRx, Inc.'s current P/E ratio is -3.0x. This places it at the 50th percentile of its historical range.
RenovoRx, Inc.'s return on equity (ROE) is -225.6%. The historical average is -193.2%.
Based on historical data, RenovoRx, Inc. is trading at a P/E of -3.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
RenovoRx, Inc. has 70.9% gross margin and -1114.0% operating margin.